The landscape of diabetes management is undergoing a exciting shift with the emergence of rapidly dissolving GLP-1 therapies. These novel formulations, designed to quickly dissolve under the sublingually, offer the opportunity for faster delivery and a minimized need for scheduled injections. This method could improve patient sticking to treatment

Viking Therapeutics has formed a mutually beneficial alliance with U.S. biopharmaceutical companies to develop and manufacture its GLP-1 drug candidate, VK2735. This marks a significant advancement in securing dependable production capabilities for these vital therapeutic agents. The agreement enables them to handle large-scale peptide manufacturin